Page last updated: 2024-09-04

cyc 202 and su 9516

cyc 202 has been researched along with su 9516 in 7 studies

Compound Research Comparison

Studies
(cyc 202)
Trials
(cyc 202)
Recent Studies (post-2010)
(cyc 202)
Studies
(su 9516)
Trials
(su 9516)
Recent Studies (post-2010) (su 9516)
979739342019

Protein Interaction Comparison

ProteinTaxonomycyc 202 (IC50)su 9516 (IC50)
Chain A, Cell division protein kinase 2Homo sapiens (human)0.13
Chain A, Cell division protein kinase 2Homo sapiens (human)0.13
Chain A, Cell division protein kinase 2Homo sapiens (human)0.13
Chain A, Cell division protein kinase 2Homo sapiens (human)0.13
photoreceptor-specific nuclear receptorHomo sapiens (human)1.194
Cyclin-T1Homo sapiens (human)1.5
G2/mitotic-specific cyclin-B2Homo sapiens (human)0.022
Cyclin-dependent kinase 1Homo sapiens (human)0.0712
Proto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)1.6
Platelet-derived growth factor receptor betaHomo sapiens (human)0.12
Cyclin-dependent kinase 4Homo sapiens (human)0.7333
Proto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)0.12
G2/mitotic-specific cyclin-B1Homo sapiens (human)0.095
Interferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)5
Cyclin-A2Homo sapiens (human)0.027
G1/S-specific cyclin-D1Homo sapiens (human)1.7
G1/S-specific cyclin-E1Homo sapiens (human)0.0887
Cyclin-dependent kinase 2Homo sapiens (human)0.0657
Vascular endothelial growth factor receptor 2Homo sapiens (human)0.1233
Glycogen synthase kinase-3 alphaHomo sapiens (human)0.35
Glycogen synthase kinase-3 betaHomo sapiens (human)0.35
Cyclin-dependent kinase 7Homo sapiens (human)0.905
Cyclin-dependent kinase 9Homo sapiens (human)1.5
Cyclin-HHomo sapiens (human)0.905
CDK-activating kinase assembly factor MAT1Homo sapiens (human)0.905
Cyclin-dependent-like kinase 5 Homo sapiens (human)0.0435
Cyclin-dependent kinase 5 activator 1Homo sapiens (human)0.022
G2/mitotic-specific cyclin-B3Homo sapiens (human)0.022

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (42.86)29.6817
2010's3 (42.86)24.3611
2020's1 (14.29)2.80

Authors

AuthorsStudies
Akula, N; Pattabiraman, N; Sridhar, J1
Bullock, AN; Fedorov, O; Knapp, S; Marsden, B; Müller, S; Pogacic, V; Rellos, P; Schwaller, J; Sundström, M1
Austin, CP; Fidock, DA; Hayton, K; Huang, R; Inglese, J; Jiang, H; Johnson, RL; Su, XZ; Wellems, TE; Wichterman, J; Yuan, J1
Akula, B; Athuluridivakar, S; Baker, SJ; Bharathi, EV; Billa, VK; Cosenza, SC; Mallireddigari, MR; Padgaonkar, A; Pallela, VR; Reddy, EP; Reddy, MV; Subbaiah, DR; Vasquez-Del Carpio, R1
Jadhav, A; Kerns, E; Nguyen, K; Shah, P; Sun, H; Xu, X; Yan, Z; Yu, KR1
Kabir, M; Kerns, E; Nguyen, K; Shah, P; Sun, H; Wang, Y; Xu, X; Yu, KR1
Kabir, M; Kerns, E; Neyra, J; Nguyen, K; Nguyễn, ÐT; Shah, P; Siramshetty, VB; Southall, N; Williams, J; Xu, X; Yu, KR1

Reviews

1 review(s) available for cyc 202 and su 9516

ArticleYear
Selectivity and potency of cyclin-dependent kinase inhibitors.
    The AAPS journal, 2006, Mar-24, Volume: 8, Issue:1

    Topics: Animals; Binding Sites; Cyclin-Dependent Kinases; Humans; Protein Kinase Inhibitors; Signal Transduction

2006

Other Studies

6 other study(ies) available for cyc 202 and su 9516

ArticleYear
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
    Proceedings of the National Academy of Sciences of the United States of America, 2007, Dec-18, Volume: 104, Issue:51

    Topics: Amino Acid Sequence; Binding Sites; Clinical Trials as Topic; Drug Evaluation, Preclinical; Enzyme Stability; Humans; Molecular Sequence Data; Phylogeny; Protein Array Analysis; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases

2007
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
    Nature chemical biology, 2009, Volume: 5, Issue:10

    Topics: Animals; Antimalarials; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosome Mapping; Crosses, Genetic; Dihydroergotamine; Drug Design; Drug Resistance; Humans; Inhibitory Concentration 50; Mutation; Plasmodium falciparum; Quantitative Trait Loci; Transfection

2009
Discovery of 8-cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonitrile (7x) as a potent inhibitor of cyclin-dependent kinase 4 (CDK4) and AMPK-related kinase 5 (ARK5).
    Journal of medicinal chemistry, 2014, Feb-13, Volume: 57, Issue:3

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cyclin-Dependent Kinase 4; Drug Screening Assays, Antitumor; Female; Heterografts; Humans; Mice; Mice, Nude; Molecular Docking Simulation; Neoplasm Transplantation; Protein Kinases; Pyridines; Pyrimidines; Repressor Proteins; Structure-Activity Relationship

2014
Highly predictive and interpretable models for PAMPA permeability.
    Bioorganic & medicinal chemistry, 2017, 02-01, Volume: 25, Issue:3

    Topics: Artificial Intelligence; Caco-2 Cells; Cell Membrane Permeability; Humans; Models, Biological; Organic Chemicals; Regression Analysis; Support Vector Machine

2017
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
    Bioorganic & medicinal chemistry, 2019, 07-15, Volume: 27, Issue:14

    Topics: Drug Discovery; Organic Chemicals; Pharmaceutical Preparations; Solubility

2019
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.
    Scientific reports, 2020, 11-26, Volume: 10, Issue:1

    Topics: Animals; Computer Simulation; Databases, Factual; Drug Discovery; High-Throughput Screening Assays; Liver; Machine Learning; Male; Microsomes, Liver; National Center for Advancing Translational Sciences (U.S.); Pharmaceutical Preparations; Quantitative Structure-Activity Relationship; Rats; Rats, Sprague-Dawley; Retrospective Studies; United States

2020